Advertisement
Advertisement
U.S. Markets close in 2 hrs 8 mins
Advertisement
Advertisement
Advertisement
Advertisement

Halozyme Therapeutics, Inc. (HALO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
56.61-0.44 (-0.77%)
As of 01:52PM EST. Market open.
Advertisement

Halozyme Therapeutics, Inc.

11388 Sorrento Valley Road
San Diego, CA 92121
United States
858 794 8889
https://www.halozyme.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees145

Key Executives

NameTitlePayExercisedYear Born
Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.Pres, CEO & Director1.65M14.1M1963
Dr. Michael J. LaBarre Ph.D.Chief Technical Officer779.55k4.42M1964
Ms. Nicole LaBrosseCFO & DirectorN/AN/A1983
Ms. Tram BuiVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Mr. Mark Snyder Esq.Gen. Counsel, Chief Compliance Officer & Corp. Sec.N/AN/AN/A
Ms. Amy Marinne FoxChief HR OfficerN/AN/AN/A
Dr. Steve Knowles MBBSChief Medical OfficerN/AN/AN/A
Mr. Todd ButlerChief of Staff to the CEO, VP & Head of Project ManagementN/AN/AN/A
Dr. Christopher Bryant Ph.D.Chief Manufacturing Officer & Head of Technical OperationsN/AN/A1961
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.

Corporate Governance

Halozyme Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 1. The pillar scores are Audit: 4; Board: 1; Shareholder Rights: 3; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement